Skip to content
OrtaakarsuMedicine information

Source-based interaction record

Aurorix 150 mg + Metaxalone

Aurorix 150 mg + Metaxalone: published drug interaction record, medicine facts and reference links. Generic / active ingredient: Moklobemid + metaxalone.

Free preview

Essential record information

Public access

Free record overview for Aurorix 150 mg + Metaxalone. Review the medicine identities and available reference links below; detailed interaction information is in the access section.

Aurorix 150 mg

Active ingredient / generic name
Moklobemid
ATC code
N06AG02

Metaxalone

Active ingredient / generic name
metaxalone
Record type
Published interaction record
Source record version
USPI revised 2026-05; SPL v5 effective 2026-05-05; checked 2026-11-05
Record sources

Source checked:

A source check is not an independent clinical review.

Access to this record

Free preview
Medicine identities, available source links and, where available, selected low-level related interaction records.
Paid details
The selected pair’s available detailed interaction explanation, mechanism and clinical context can be read with single-page access or an eligible membership page allowance.

A single-page purchase unlocks this resource only. Membership provides the page allowance shown in your plan; it does not unlock every related record automatically.

  • This page only: 6.00 USD One-time payment
  • Monthly membership: 40.00 USD / month · starting price

A free account with a verified email address is required before checkout. Monthly membership renews automatically with no trial period. Taxes and the final total appear in checkout.

Examples selected from real records

Selected free interaction examples

Free

These examples concern other medicine pairs involving the medicines above. They do not assess the main pair on this page.

Published related records: 245. The selection below does not represent the complete list.

No eligible low-level example is currently selected for this section. This does not mean that other interactions do not exist.

Examples selected from real records

Published records

The identity and source of these published related records are shown below. Clinical details are displayed according to your access to each record.

Details of this record

Access this interaction record

Basic facts and available reference links are free. The headings below identify the paid details present in this record; clinical content is read after access is unlocked.

Sections available in this record

  • Interaction explanation
  • Interaction mechanism
  • Interaction context and scope

Review the free record and source informationSource checked:

This page only

6.00 USDOne-time payment

Permanent access to this record and its available language versions. No subscription required.

For returning to one record. No monthly subscription.

Buy access to this page

Monthly membership

40.00 USD/ month · starting price

30 different records per billing period. Reading a record again in the same period does not use another page allowance.

For exploring multiple records. Pages unlocked with membership are readable during that billing period.

Explore memberships

Monthly memberships renew automatically; there is no trial period. Taxes and the final total appear in checkout.

A verified account is required. Turkish and English versions of the same resource share one access right.

This information is not personal treatment advice. Discuss treatment decisions with your doctor or pharmacist.